Ganciclovir eye drop for the treatment of cytomegalovirus anterior uveitis

Ganciclovir eye drop for the treatment of cytomegalovirus anterior uveitis - Ganciclovir eye drop for CMV anterior uveitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007127

Enrollment

Registered

2012-03-10

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cytomegalovirus anterior uveitis

Interventions

Ganciclovir eye drop (0.5%) is applied four times a day in the affected eye.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients with cytomegalovirus anterior uveitis who are under hospitalization or going to hospital regularly

Exclusion criteria

Exclusion criteria: (1) the patients who refsed the consent for this study (2) the patient judged to be unsuitable for study participation by doctor in charge

Design outcomes

Primary

Measure	Time frame
visual acuity, intraocular pressure, and the degree of anterior segment inflammation	—

Countries

Japan

Contacts

Public ContactSentaro Kusuhara

Kobe University Graduate School of Medicine Division of Ophthalmology, Department of Surgery

kusu@med.kobe-u.ac.jp078-382-6048

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026